InsiderPulse
Dashboard

INCY

Incyte Corporation

Health CareRussell 2000

Incyte Corporation insider trading

Incyte Corporation files with the SEC as a Services-Commercial Physical & Biological Research company headquartered in Wilmington, DE. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent INCY insider transactions

4 insiders traded INCY on the open market between Jul 15, 2026 and Sep 15, 2026 — 22 sales worth $18.2M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$18.2M

22 of 22 on a 10b5-1 plan

Net
−$18.2M
Insiders
4

Open-market purchases (code P) and sales (code S) from Incyte Corporation's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every INCY Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

INCY insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 13 insiders traded INCY on the open market: 0 purchases and 67 sales worth $50.9M, every sale pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 43 sales ($43.5M), by 12 insiders.

QuarterBoughtSold
Q2 2026—−$3.7M4 sales · all on a plan
Q1 2026—−$6.4M4 sales · all on a plan
Q4 2025—−$30M19 sales · all on a plan
Q3 2025—−$3.4M16 sales · all on a plan
Q2 2025—−$227.6K3 sales · all on a plan
Q1 2025—−$3.3M7 sales · all on a plan
Q4 2024—−$839.7K6 sales · all on a plan
Q3 2024—−$3M8 sales · all on a plan
Largest sale
−$19.8M of INCY by Hoppenot Herve (Director) on Nov 10, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Tray Thomas10b5-1

    Principal Accounting Officer

    −$263.9K

    Jun 04, 2026

    2,639 sh · $100.00

  • Tray Thomas10b5-1

    Principal Accounting Officer

    −$199.7K

    May 26, 2026

    2,051 sh · $97.35

  • Clancy Paul J10b5-1

    Director

    −$1.4M

    May 19, 2026

    15,000 sh · $94.93

  • Cagnoni Pablo J10b5-1

    President, Global Head of R&D

    −$1.8M

    Apr 17, 2026

    18,667 sh · $96.50

  • Cagnoni Pablo J10b5-1

    President, R&D

    −$1.8M

    Mar 17, 2026

    18,667 sh · $94.24

  • Cagnoni Pablo J10b5-1

    President, R&D

    −$1.9M

    Feb 19, 2026

    18,668 sh · $100.91

  • Issa Mohamed Khairie10b5-1

    EVP, Head of US Oncology

    −$1.2M

    Jan 07, 2026

    10,856 sh · $109.07

  • Stein Steven H10b5-1

    EVP & Chief Medical Officer

    −$1.6M

    Jan 05, 2026

    15,634 sh · $101.70

  • Tray Thomas10b5-1

    Principal Accounting Officer

    −$277.4K

    Dec 19, 2025

    2,774 sh · $100.00

  • Tray Thomas10b5-1

    Principal Accounting Officer

    −$59K

    Dec 18, 2025

    600 sh · $98.25

  • Morrissey Michael James10b5-1

    EVP, Head of Tech. Operations

    −$420.5K

    Dec 17, 2025

    4,323 sh · $97.26

  • Morrissey Michael James10b5-1

    EVP, Head of Tech. Operations

    −$5.2M

    Dec 16, 2025

    53,175 sh · $97.29

  • Morrissey Michael James10b5-1

    EVP, Head of Tech. Operations

    −$81.2K

    Dec 16, 2025

    833 sh · $97.42

  • Mayes Patrick A10b5-1

    EVP & Chief Scientific Officer

    −$24.2K

    Dec 11, 2025

    255 sh · $94.94

  • Mayes Patrick A10b5-1

    EVP & Chief Scientific Officer

    −$530.8K

    Dec 10, 2025

    5,553 sh · $95.58

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Incyte Corporation company record

SEC industry classification
Services-Commercial Physical & Biological Research
Headquarters
Wilmington, DE
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0000879169
Previously filed as
INCYTE INC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought INCY

What the stock actually did in the 90 days following each open-market purchase

Don't check INCY — let it ping you

Get told the moment an insider moves on INCY

Pro watches Incyte Corporation for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add INCY to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track INCY on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read INCY insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

JAZZHALOEXASNTRACRSPNTLABEAMRXRXTWSTPACBARWRIONS
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are INCY insiders buying or selling?
Between Jul 15, 2026 and Sep 15, 2026, 4 Incyte Corporation insiders made no open-market purchases and 22 sales worth $18.2M, a net sale of $18.2M. 22 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much INCY stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 13 Incyte Corporation insiders made no open-market purchases and 67 sales worth $50.9M. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 43 sales ($43.5M). The largest sale was Hoppenot Herve selling $19.8M on Nov 10, 2025.
What was the largest recent INCY insider trade?
Stein Steven H (CMO & Head of Late-Stage Dev.) sold $3.2M of INCY stock on Jul 15, 2026 at about $113.05 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy INCY shares?
No open-market purchase by a Incyte Corporation insider appears in the filings from Jul 15, 2026 to Sep 15, 2026 — every recorded open-market transaction in that period was a sale.
Where does INCY insider trading data come from?
From the Form 4 filings Incyte Corporation's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.